Fabry disease

Area of Science:

• Genetics and rare diseases
• Metabolic disorders
• Neurology

Background:

• Fabry disease is an X-linked genetic disorder caused by mutations in the GLA gene, leading to alpha-galactosidase A deficiency.
• This deficiency results in the accumulation of glycosphingolipids, causing multi-organ dysfunction and systemic vasculopathy.
• Fabry disease complications, including stroke, neuropathy, cardiac, and kidney issues, are often clinically indistinguishable from common disorders, leading to underdiagnosis.

Purpose of the Study:

• To review the current understanding of Fabry disease etiology and pathogenesis.
• To discuss the diagnostic challenges and the potential for increased incidence due to underdiagnosis.
• To explore the evolving therapeutic landscape and the role of standard management strategies.

Main Methods:

• Literature review of recent studies on Fabry disease genetics, clinical manifestations, and therapeutic advancements.
• Analysis of the mechanisms underlying glycosphingolipid accumulation and its organ-specific effects.
• Evaluation of the efficacy of both specific and non-specific therapies in managing Fabry disease.

Main Results:

• GLA gene mutations are the cause of Fabry disease, impacting multiple organ systems.
• The disease presents with non-specific symptoms, contributing to its underdiagnosis.
• While specific therapies are emerging, standard medical and surgical treatments remain vital for managing organ dysfunction and slowing disease progression.

Conclusions:

• Fabry disease is an underdiagnosed condition with significant systemic implications.
• Understanding the pathogenic mechanisms is key to developing effective treatments.
• A combination of vigilant monitoring, early diagnosis, and comprehensive management, including standard therapies, is essential for improving patient outcomes.